Company Madrigal Pharmaceuticals, Inc.

Equities

MDGL

US5588681057

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-23 pm EDT			5-day change	1st Jan Change
234.8 ^USD	-0.09%		+8.14%	+1.50%

May. 19	Certain Common Stock of Madrigal Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 19-MAY-2024.	CI
May. 19	Certain Warrants of Madrigal Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 19-MAY-2024.	CI

Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH). The Company's product candidate, resmetirom, is a once-daily, oral, liver-directed thyroid hormone receptor-Î² (THR-Î²) agonist designed to target key underlying causes of NASH. NASH is a more advanced form of non-alcoholic fatty liver disease (NAFLD). The Companyâs clinical development program includes MAESTRO-NASH, MAESTRO-NAFLD-1, and MAESTRO-NASH OUTCOMES.

Number of employees: 376

Managers	Title	Age	Since
Edward Chiang FOU	Founder	-	11-08-31
William Sibold CEO	Chief Executive Officer	-	23-09-07
Rebecca Taub FOU	Founder	71	16-06-30
Ronald Filippo CTO	Chief Tech/Sci/R&D Officer	-	Nov. 20
Stephen Dodge CTO	Chief Tech/Sci/R&D Officer	-	-
Paul Friedman BRD	Director/Board Member	81	16-07-21
Tina Ventura IRC	Investor Relations Contact	-	Jan. 28
Carole Huntsman PRN	Corporate Officer/Principal	-	-
Dominic F. Labriola PRN	Corporate Officer/Principal	-	22-01-09
Robert Waltermire PRN	Corporate Officer/Principal	60	21-08-01

Members of the board	Title	Age	Since
Fred Craves FOU	Founder	78	11-08-31
Julian Baker CHM	Chairman	57	23-06-14
Ken Bate BRD	Director/Board Member	73	16-07-21
Paul Friedman BRD	Director/Board Member	81	16-07-21
Richard Levy BRD	Director/Board Member	66	16-08-10
Rebecca Taub FOU	Founder	71	16-06-30
William Sibold CEO	Chief Executive Officer	-	23-09-07
James Daly BRD	Director/Board Member	63	19-06-26
Raymond Cheong BRD	Director/Board Member	42	23-06-14

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	21,311,526	17,609,651 ( 82.63 %)	0	82.63 %

Name	Equities	%	Valuation
Janus Henderson Investors US LLC 14.49 %	3,042,661	14.49 %	591 M $
Janus Henderson Investors US LLC 12.39 %	2,601,282	12.39 %	506 M $
Baker Bros. Advisors LP 9.383 %	1,969,798	9.383 %	383 M $
Avoro Capital Advisor LLC 9.262 %	1,944,444	9.262 %	378 M $
Avoro Capital Advisor LLC 8.997 %	1,888,888	8.997 %	367 M $
Paulson & Co., Inc. 8.455 %	1,775,000	8.455 %	345 M $
Rebecca Taub 8.314 %	1,745,342	8.314 %	339 M $
Vanguard Fiduciary Trust Co. 7.949 %	1,668,806	7.949 %	324 M $
BlackRock Advisors LLC 5.462 %	1,146,683	5.462 %	223 M $
Paulson & Co., Inc. 5.267 %	1,105,741	5.267 %	215 M $

Name	Equities	%	Valuation
Baker Bros. Advisors LP 100.00 %	1,969,797	100.00 %	383 M $

Madrigal Pharmaceuticals, Inc.

200 Barr Harbor Drive Suite 200

19428, West Conshohocken

+267 824 2827

http://www.madrigalpharma.com

address Madrigal Pharmaceuticals, Inc.(MDGL)

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

235.1 USD

Average target price

363.9 USD

Spread / Average Target

+54.79%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
MADRIGAL PHARMACEUTICALS, INC.	+1.50%	5.01B
VERTEX PHARMACEUTICALS INCORPORATED	+10.79%	115B
REGENERON PHARMACEUTICALS, INC.	+11.65%	106B
BIONTECH SE	-6.20%	24.69B
ARGENX SE	-2.33%	21.97B
GENMAB A/S	-6.03%	19.27B
BEIGENE, LTD.	-13.41%	17.56B
WUXI APPTEC CO., LTD.	-40.50%	17.32B
NEUROCRINE BIOSCIENCES, INC.	+6.64%	14.03B
SAREPTA THERAPEUTICS, INC.	+31.84%	12.13B

Bio Therapeutic Drugs